Verici DX
VRCI · AIM · Health Care · mcap £5.1m · 0.2p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Offer | WRAP Retail Offer for up to £250,000
Verici Dx raises £8.5m through placing and offers up to £250k retail share issue at £0.002 per share. |
+0.0% |
| 09 Oct 26 | Fundraise | Result of Placing
Verici Dx raised £8.5 million through placing of 4.25 billion shares at 0.20 pence per share. |
+0.0% |
| 09 Oct 26 | Close of Accelerated Bookbuild
Accelerated bookbuild for placing successfully closed; retail offer to follow separately. |
+0.0% | |
| 08 Oct 26 | Fundraise | Launch of Proposed Placing
Verici Dx launching placing of 4bn shares at 0.2p to raise £8m, with retail offer of up to £250k. |
+0.0% |
| 01 Oct 26 | Capital Access Window - Verici Dx PLC | +0.0% | |
| 30 Sep 26 | Results | Half-year Results
H1 2026 revenues $1.8m with Tutivia testing up 53%; cash $2.4m; further fundraise proposed. |
+7.1% |
| 30 Sep 26 | Fundraise | Proposed Fundraise and Capital Access Window
Verici Dx announces proposed equity fundraise; trading paused under AIM Capital Access Window. |
+7.1% |
| 21 Sep 26 | Q4 launch of TranscripTx™ genetic test
Verici Dx to launch TranscripTx, a genetic test for transplant patients, in Q4 2026. |
+0.0% | |
| 11 Aug 26 | Certified Service Provider agreement with Olink®
Verici Dx achieved Olink Certified Service Provider status to offer proteomics assay services. |
+11.1% | |
| 06 Jul 26 | Investor presentation
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, will provide a live online presentation relating to the Company's final results announced on 29 June 2026, and recent fundrais |
+0.0% | |
| 29 Jun 26 | Results | Final Results
FY25 revenues $3.7m, Tutivia test orders up 250%, Medicare coverage secured covering 68% of US transplant tests. |
+0.0% |
| 24 Jun 26 | New York State clinical lab certification received
Verici Dx receives New York State clinical lab certification, completing authorisation for Tutivia test in all 50 US states. |
+0.0% | |
| 12 Jun 26 | Fundraise | Result of WRAP Retail Offer
WRAP Retail Offer raises £0.19m at 0.35p per share; total fundraise with Placing is £2.6m. |
+0.0% |
| 08 Jun 26 | Offer | WRAP Retail Offer for up to £200,000
Verici Dx launches retail offer for up to £200,000 alongside £2.5m placing at 0.35p per share. |
+6.7% |
| 05 Jun 26 | Fundraise | Result of Placing & raising gross proceeds c£2.5m
Placing completed raising gross proceeds of £2.5 million at 0.35 pence per share. |
−11.8% |
| 05 Jun 26 | Fundraise | Proposed Fundraising via Placing
Verici Dx proposes £2.5m placing at 0.35p per share, representing 17.6% discount to prior close. |
−11.8% |
| 02 Jun 26 | Study validating economic advantages of PTRA test
Health economic study published showing PTRA test could generate $191m in U.S. kidney transplant healthcare savings over two years. |
+0.0% | |
| 02 Jun 26 | AMA grants additional CPT® Code for ProtegaTM
AMA grants CPT code X257U for Protega test, effective October 2026, first step toward US commercialisation. |
+0.0% | |
| 19 May 26 | Clinical study validating PTRA test published
Peer-reviewed study published validating PTRA test for predicting early acute kidney transplant rejection. |
+0.0% | |
| 16 Apr 26 | Trading update | Positive Q1 Trading Update
Q1 testing volumes grew 32% quarter-on-quarter to 392, ahead of management expectations, with seven new transplant centres ordering. |
+9.5% |
| 31 Mar 26 | Board change | Directorate Change
Non-Executive Director James McCullough resigned to focus on CEO role at Renalytix plc. |
+0.0% |
| 05 Feb 26 | Trading update | FY25 Trading Update
FY25 revenues $3.8m with $3.0m from Tutivia tests; Medicare coverage secured for 68% of US transplant tests. |
+0.0% |
| 05 Feb 26 | Agreement with BCBS of Illinois for Tutivia™
Verici Dx secures agreement with Blue Cross and Blue Shield of Illinois for Tutivia kidney transplant test coverage. |
+0.0% | |
| 12 Nov 25 | Completion of CAP accreditation audit
Verici Dx completed second biennial CAP accreditation audit with no deficiencies. |
+2.3% | |
| 06 Nov 25 | Provider Participation Agreement with Prime Health
Signed Provider Participation Agreement with Prime Health Services to expand US commercial reach and coverage from private payors. |
+16.0% | |
| 03 Nov 25 | Completion of ISO 27001 surveillance audit
Verici Dx successfully completed annual ISO 27001:2022 surveillance audit for data security compliance. |
−3.6% | |
| 30 Oct 25 | Options revision & Grant of new share options
Repriced existing share options for three directors and granted new options to directors, employees and consultants. |
−3.4% | |
| 06 Oct 25 | Board change | Directorate Change
Aubrey Powell appointed as Non-executive Director; Dr Erik Lium steps down. |
+11.5% |
| 06 Oct 25 | Update on Tutivia™ test adoption
Tutivia test adoption expanding with 19% increase in ordering clinicians and nine new transplant centres onboarded in Q3. |
+11.5% |
Company filings. Not investment advice.